Top 25 Translational Regenerative Medicine Manufacturers 2019
In 2018, the global translational regenerative medicine is estimated at $28bn. The global translational regenerative medicine market is highly competitive and fragmented with the presence of several vendors. The competition is likely to increase with advances in R&D and technological innovations. The market is characterized by the presence of well-diversified international and local vendors that provide cost-effective products with limited features and functionalities.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you will find 230-page report and you will receive 120 tables and 70 figures – all unavailable elsewhere.
The 230-page report provides clear detailed insight into the Top 25 Translational Regenerative Medicine Manufacturers 2019. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
- This report discusses the global translational regenerative medicine market and provides revenue forecast to 2028 for this market and its leading submarkets:
- Stem Cells
- Tissue Engineering
- Gene Therapy
- This report discusses several translational regenerative medicine products and provides revenue forecast to 2028 for:
- Osteocel Plus
- Apligraf
- Grafix/Stravix
- ReCell
- Assessment of the 25 leading manufacturers in the global translational regenerative medicine market:
- Acelity
- Alphatec Spine
- Anika Therapeutics
- Arthesys
- Avita Medical
- Integra Lifesciences
- Medipost
- Medtronic
- Mesoblast
- NuVasive
- Organogenesis
- Orthofix International
- TiGenix
- UniQure
- Vericel Corporation
- Other companies
- Of the top 25 translational regenerative medicine manufacturers, the report provides revenue forecast for 22 of these companies for the period of 2018 to 2028.
- Qualitative analysis of the translational regenerative medicine market: PESTEL analysis, Porter’s Five Forces analysis, factors that drive and restrain the market, opportunity and trends in the market.
- This report discusses the regulation of regenerative medicine in the US, Japan, China, Australia, India and Ireland.
- Key questions answered by this report:
- Who are the leading Translational Regenerative Medicine (TRM) manufacturers?
- What factors are driving and restraining the growth of these leading TRM manufacturers?
- How have the leading TRM manufacturers performed financially in recent years?
- Which TRM manufacturer will experience revenue growth over the coming years?
- What strategies have TRM manufacturers been implementing for sales growth in recent years?
- Which technologies will be crucial to TRM manufacturers from 2018 to 2028?
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Overview of the Top Translational Regenerative Medicine Manufacturers
- 1.2 Why You Should Read This Report
- 1.3 How This Report Delivers
- 1.4 Main Questions Answered by This Analytical Study
- 1.5 Who is This Report For?
- 1.6 Methodology
- 1.7 Frequently Asked Questions (FAQ)
- 1.8 Associated Visiongain Reports
- 1.9 About Visiongain
- 2. Translational Regenerative Medicine Market Landscape
- 2.1 Introduction to Translational Regenerative Medicine
- 2.1.1 What is Regenerative Medicine?
- 2.1.2 Translational Regenerative Medicine – From Bench to Bedside
- 2.1.3 Translational Regenerative Medicine Segments
- 2.2 Stem Cell Therapy Definition and Overview
- 2.2.1 How Embryonic Stem Cells (ESCs) Entered the Fray
- 2.2.2 Classifying Stem Cells by Potency
- 2.2.3 Stem Cells Categories: ESCs, SSCs, iPSCs
- 2.2.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
- 2.2.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
- 2.3 Tissue Engineering Definition and Overview
- 2.4 Gene Therapy Definition and Overview
- 2.4.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
- 2.5 Other Approaches to Regenerative Medicine
- 2.5.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
- 2.5.2 Cosmetic Applications of Regenerative Medicine
- 2.6 Regulation of Regenerative Medicine
- 2.6.1 Regulation of Regenerative Medicine Products in Europe
- 2.6.2 Regulation of Regenerative Medicine Products in the US
- 2.6.3 Regulation of Regenerative Medicine Products in Japan
- 2.6.4 Regulation of Regenerative Medicine Products in China
- 2.6.5 Regulation of Regenerative Medicine Products in Australia
- 2.6.6 Regulation of Regenerative Medicine Products in India
- 2.6.7 Regulation of Regenerative Medicine Products in Ireland
- 2.7 The Phases of Clinical Trials
- 2.8 Global Translational Regenerative Medicine: Market Overview & Market Revenue Forecast, 2018-2028
- 2.9 Market Dynamics
- 2.9.1 Driving and Restrictive Forces for Translational Regenerative Medicine Market, 2018
- 2.9.1.1 Market Driver:
- 2.9.1.1.1 Improvements in Regulatory Frameworks
- 2.9.1.1.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
- 2.9.1.1.3 Strong Support from Governments in Multiple Regions
- 2.9.1.1.4 Increasing Ease of Product Commercialisation and Market Access
- 2.9.1.2 Market Restraints:
- 2.9.1.2.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
- 2.9.1.2.2 Lack of Funding from Venture Capital
- 2.9.1.2.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
- 2.9.1.2.4 Successful Commercialisation of TRM Products Requires New Business Models
- 2.9.2 Opportunity and Trends in Translational Regenerative Medicine Market, 2018
- 2.9.2.1 Market Opportunities:
- 2.9.2.1.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
- 2.9.2.1.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
- 2.9.2.1.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
- 2.9.2.2 Market Threats:
- 2.9.2.2.1 Ethical Concerns Limiting R&D in Regenerative Medicine
- 2.9.2.2.2 Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies
- 2.9.2.2.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
- 2.9.2.2.4 Restraints on Reimbursement May Slow Growth
- 2.9.3 PESTEL Analysis for Global Translational Regenerative Medicine Market, 2018
- 2.9.3.1 Political
- 2.9.3.2 Economic
- 2.9.3.3 Social
- 2.9.3.4 Technological
- 2.9.3.5 Legal
- 2.9.3.6 Enviromental
- 2.9.4 Porter's Five Force Analysis for Global Translational Regenerative Medicine Market, 2018
- 2.9.4.1 Threat of New Entrants
- 2.9.4.2 Threat of Substitutes
- 2.9.4.3 Power of Suppliers
- 2.9.4.4 Power of Buyers
- 2.9.4.5 Rivalry among Competitors
- 3. Global Leading Translational Regenerative Medicine Products: Overview, 2018
- 3.1 Stem Cell Therapy
- 3.1.1 Cx601 (TiGenix)
- 3.1.2 NiCord (Gamida Cell Ltd.)
- 3.1.3 Osteocel Plus (NuVasive)
- 3.1.3.1 Osteocel Plus: Sales Forecast 2018-2028
- 3.2 Tissue Engineering
- 3.2.1 Apligraf (Organogenesis, Inc.)
- 3.2.1.1 Apligraf: Sales Forecast 2018-2028
- 3.2.2 Grafix (Osiris Therapeutics, Inc.)
- 3.2.2.1 Grafix: Sales Forecast 2018-2028
- 3.2.3 ReCell (Avita Medical)
- 3.2.3.1 ReCell (Avita Medical): Sales Forecast 2018-2028
- 3.3 Gene Therapy
- 3.3.1 RT-100 (AC6 Gene Transfer) (Renova Therapeutics)
- 3.3.2 OXB 201 (Oxford Biomedica Plc)
- 3.3.3 LUXTURNA (voretigene neparvovec) (Spark Therapeutics, Inc)
- 4. Leading Global Translational Regenerative Medicine Manufacturers, 2018
- 4.1 Translational Regenerative Medicine: Leading Companies
- 4.2 Alphatec Spine, Inc.
- 4.2.1 Alphatec Spine, Inc: Financial and Performance Analysis, 2012-2017
- 4.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
- 4.2.3 Alphatec Spine, Inc: Revenue Forecast, 2018-2028
- 4.3 Anterogen Co Ltd.
- 4.3.1 Anterogen Co Ltd: Financial and Performance Analysis, 2014-2017
- 4.3.2 Anterogen Co Ltd: Regenerative Medicine Product Portfolio, 2017
- 4.3.3 Anterogen Co Ltd: Pipeline Analysis, 2017
- 4.3.4 Anterogen Co Ltd: Revenue Forecast, 2018-2028
- 4.4 Athersys Inc
- 4.4.1 Athersys Inc: Financial and Performance Analysis, 2012-2017 & Revenue Forecast, 2018-2028
- 4.4.2 Athersys Inc: Key Developments in Regenerative Medicine Segment
- 4.4.3 Athersys Inc: Pipeline Analysis, 2017
- 4.4.3.1 MultiStem Technology – Potential Treatment for a Range of Diseases
- 4.5 Avita Medical Ltd
- 4.5.1 Avita Medical Ltd: Financial and Performance Analysis, 2013-2017 & Revenue Forecast, 2018-2028
- 4.5.2 Avita Medical Ltd: Regenerative Medicine Portfolio, 2017
- 4.5.3 Avita Medical Ltd: Key Developments in Regenerative Medicine Segment
- 4.5.4 Avita Medical Ltd: Pipeline Analysis, 2017
- 4.6 AxoGen, Inc.
- 4.6.1 AxoGen, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.6.2 AxoGen, Inc: Regenerative Medicine Portfolio, 2017
- 4.6.3 AxoGen, Inc: Pipeline Analysis, 2017
- 4.7 Medipost, Co Ltd.
- 4.7.1 Medipost Co Ltd: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.7.2 Medipost Co Ltd: Regenerative Medicine Portfolio, 2017
- 4.7.3 Medipost Co Ltd: Pipeline Analysis, 2017
- 4.8 Mesoblast Ltd
- 4.8.1 Mesoblast, Ltd: Financial and Performance Analysis, 2012-2017 and Revenue Forecast, 2018-2028
- 4.8.2 Mesoblast, Ltd Product Portfolio, 2017
- 4.8.3 Mesoblast, Ltd: Pipeline Analysis, 2017
- 4.8.3.1 NeoFuse
- 4.8.3.2 Chondrogen
- 4.8.3.3 Prochymal / TEMCELL
- 4.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
- 4.9 NuVasive, Inc
- 4.9.1 NuVasive, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.9.2 NuVasive, Inc Product Portfolio, 2017
- 4.9.3 NuVasive: Pipeline Analysis, 2017
- 4.10 BioTime, Inc.
- 4.10.1 Biotime, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.10.2 BioTime, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.10.3 BioTime, Inc: Key Developments in Regenerative Medicine Segment
- 4.10.4 BioTime, Inc: Pipeline Analysis, 2018
- 4.11 Organogenesis
- 4.11.1 Organogenesis, Inc: Regenerative Medicine Portfolio, 2017
- 4.11.2 Organogenesis, Inc: Key Developments in Regenerative Medicine Segment
- 4.11.3 Organogenesis, Inc: Pipeline Analysis, 2017
- 4.12 Pharmicell, Co Ltd.
- 4.12.1 Pharmicell, Co Ltd: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.12.2 Pharmicell, Co Ltd: Pipeline Analysis, 2017
- 4.13 Regenerys, Ltd
- 4.13.1 Regenerys, Ltd: Regenerative Medicine Portfolio, 2017
- 4.13.2 Regenerys: Pipeline Analysis, 2017
- 4.14 TiGenix
- 4.14.1 TiGenix NV: Regenerative Medicine Product Portfolio, 2017
- 4.14.2 TiGenix NV: Key Developments in Regenerative Medicine Segment
- 4.14.3 TiGenix: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.14.4 TiGenix: Pipeline Analysis, 2017
- 4.15 UniQure
- 4.15.1 Uniqure: Regenerative Medicine Product Portfolio, 2017
- 4.15.2 Uniqure: Financial and Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028
- 4.15.3 UniQure: Recent Major Acquisition and Collaboration
- 4.15.4 UniQure: Pipeline Analysis, 2017
- 4.16 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)
- 4.16.1 Vericel Corporation: Regenerative Medicine Portfolio, 2017
- 4.16.2 Vericel’s Acquisition of Sanofi’s Regenerative Medicine Business
- 4.16.3 Vericel Corporation: Historical Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.16.4 Vericel Corporation: Pipeline Analysis, 2017
- 4.16.4.1 The ixCELL-DCM Clinical Trial
- 4.17 Anika Therapeutics, Inc.
- 4.17.1 Anika Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.17.2 Anika Therapeutics, Inc: Key Developments in Regenerative Medicine Segment
- 4.17.3 Anika Therapeutics, Inc: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.17.4 Anika Therapeutics, Inc: Pipeline Analysis, 2017
- 4.18 Orthofix International, Inc.
- 4.18.1 Orthofix International, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.18.2 Orthofix International, Inc: Key Developments in Regenerative Medicine Segment
- 4.18.3 Orthofix International, Inc: Historical Financial & Performance Analysis, 2012-2017 and Revenue Forecast, 2018-2028
- 4.18.4 Orthofix International, Inc: Pipeline Analysis, 2017
- 4.19 Medtronic, Plc.
- 4.19.1 Medtronic, Plc: Product Portfolio, 2017
- 4.19.2 Medtronic, Plc: Key Developments in Regenerative Medicine Segment
- 4.19.3 Medtronic, Plc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast 2018-2028
- 4.19.4 Medtronic, Plc: Pipeline Analysis, 2017
- 4.20 Stryker Corporation
- 4.20.1 Stryker Corporation: Regenerative Medicine Product Portfolio, 2017
- 4.20.2 Stryker Corporation: Key Developments in Regenerative Medicine Segment
- 4.20.3 Stryker Corporation: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.21 Acelity, Inc.
- 4.21.1 Acelity, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.21.2 Acelity, Inc: Key Developments in Regenerative Medicine Segment
- 4.21.3 Acelity, Inc: Historical Financial & Performance Analysis, 2011-2015 and Revenue Forecast, 2018-2028
- 4.22 Brainstorm Cell Therapeutics, Inc.
- 4.22.1 Brainstorm Cell Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.22.2 Brainstorm Cell Therapeutics, Inc: Key Developments in Regenerative Medicine Segment
- 4.22.3 Brainstorm Cell Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017
- 4.22.4 Brainstorm Cell Therapeutics, Inc: Pipeline Analysis, 2017
- 4.23 Integra Lifesciences.
- 4.23.1 Integra Lifesciences: Regenerative Medicine Product Portfolio, 2017
- 4.23.2 Integra Lifesciences: Key Developments in Regenerative Medicine Segment
- 4.23.3 Integra Lifesciences: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028
- 4.24 Sangamo Therapeutics, Inc
- 4.24.1 Sangamo Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.24.2 Sangamo Therapeutics, Inc: Key Developments in Regenerative Medicine Segment
- 4.24.3 Sangamo Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028
- 4.24.4 Sangamo Therapeutics, Inc: Pipeline Analysis, 2017
- 4.25 Japan Tissue Engineering, Co Ltd (J-Tec)
- 4.25.1 Japan Tissue Engineering, Co Ltd: Regenerative Medicine Product Portfolio, 2017
- 4.25.2 Japan Tissue Engineering, Co Ltd: Key Developments in Regenerative Medicine Segment
- 4.25.3 Japan Tissue Engineering, Co Ltd: Historical Financial & Performance Analysis, 2014-2017 and Revenue Forecast, 2018-2028
- 4.25.4 Japan Tissue Engineering, Co Ltd: Pipeline Analysis, 2017
- 4.26 Cytori Therapeutics, Inc.
- 4.26.1 Cytori Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017
- 4.26.2 Cytori Therapeutics, Inc: Key Developments In Regenerative Medicine Segment
- 4.26.3 Cytori Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028
- 4.26.4 Cytori Therapeutics, Inc: Pipeline Analysis, 2017
- 5. Conclusion
- 5.1 Overview of Current Market Competition and Competitor Forecast, 2018-2028
- 5.2 Leading Regenerative Medicine Players in 2017 and 2018
- 5.2.1 Acelity, Inc
- 5.2.2 Organogenesis Inc
- 5.2.3 Uniqure
- 5.2.4 TiGenix NV
- 5.2.5 Vericel Corporation
- 5.3 Future Outlook of Top 10 TRM competitors, 2018-2028
- 5.3.1 Medtronic PLC
- 5.3.2 Acelity
- 5.3.3 Integra Lifesciences
- 5.3.4 NuVasive, Inc
- 5.3.5 Orthofix International NV
- 5.3.6 Anika Therapeutics, Inc
- 5.3.7 Organogenesis
- 5.3.8 Uniqure
- 5.3.9 TiGenix NV
- 5.3.10 Vericel Corporation
- 5.3.11 R&D Pipeline Products Crucial to Future Market Growth
- 5.4 What Does the Future Hold for Regenerative Medicine?
- Appendices
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain report evaluation form
- List of Tables
- Table 2.1 European Union Definitions of Regenerative Medicine Products, 2018
- Table 2.2 Potency and Source of Stem Cells, 2018
- Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2018
- Table 2.4 Major Types of Stem Cells and Their Properties, 2018
- Table 2.5 Terminology for Stem Cell Donor-Types, 2018
- Table 2.6 Clinical Trial Phases, 2018
- Table 2.7 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2017-2022
- Table 2.8 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2023-2028
- Table 2.9 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2018-2028
- Table 3.1 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022
- Table 3.2 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028
- Table 3.3 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022
- Table 3.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028
- Table 3.5 Grafix/Stravix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022
- Table 3.6 Grafix/Stravix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028
- Table 3.7 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022
- Table 3.8 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028
- Table 4.1 Alphatec Spine Details, 2018
- Table 4.2 Alphatec Spine, Inc: Historical Sales ($m) and Operating Profit / Loss ($m), 2012-2017
- Table 4.3 Alphatec Spine: Regenerative Medicine Clinical Trials, 2017
- Table 4.4 Forecast Alphatec Spine: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.5 Anterogen Co Ltd Details, 2018
- Table 4.6 Anterogen Co Ltd: Historical Sales ($m) and Operating Profit / Loss ($m), 2014-2017
- Table 4.7 Anterogen: Regenerative Medicine Clinical Trials, 2017
- Table 4.8 Forecast Anterogen: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.9 Athersys Inc, Details, 2018
- Table 4.10 Athersys Inc: Historical Sales ($m) 2012-2017
- Table 4.11 Athersys Inc: Historical Expenditure and Losses ($m) 2012-2017
- Table 4.12 Forecast Athersys Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.13 Athersys Inc: Regenerative Medicine Clinical Trials, 2018
- Table 4.14 Avita Medical Ltd Details, 2018
- Table 4.15 Avita Medical Ltd: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2017
- Table 4.16 Forecast Avita Medical Ltd: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.17 Avita Medical: Regenerative Medicine Clinical Trials, 2017
- Table 4.18 AxoGen Inc. Details, 2018
- Table 4.19 AxoGen, Inc: Historical Sales ($m) and Net Loss ($m), 2013-2017
- Table 4.20 Forecast AxoGen, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.21 AxoGen, Inc: Regenerative Medicine Clinical Trials, 2017
- Table 4.22 Medipost Co Ltd Details, 2018
- Table 4.23 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2017
- Table 4.24 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2017
- Table 4.25 Forecast Medipost: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.26 Medipost: Regenerative Medicine Clinical Trials, 2017
- Table 4.27 Mesoblast Ltd Details, 2018
- Table 4.28 Mesoblast: Historical Sales ($m, AUD m), 2012-2017
- Table 4.29 Forecast Mesoblast: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.30 Mesoblast: Regenerative Medicine Clinical Trials, 2017
- Table 4.31 Nuvasive, Inc Details, 2018
- Table 4.32 NuVasive, Inc: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2013-2017
- Table 4.33 Forecast NuVasive, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.34 NuVasive: Regenerative Medicine Clinical Trials, 2017
- Table 4.35 BioTime, Inc Details, 2018
- Table 4.36 BioTime Inc: Historical Sales ($m) and Gross Income ($m), 2013-2017
- Table 4.37 Forecast BioTime Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.38 Biotime, Inc: Regenerative Medicine Clinical Trials, 2018
- Table 4.39 Organogenesis Inc, Details, 2018
- Table 4.40 Organogenesis: Regenerative Medicine Clinical Trials, 2018
- Table 4.41 Pharmicell, Co Ltd, Details, 2018
- Table 4.42 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2013-2016
- Table 4.43 Forecast Pharmicell: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.44 Pharmicell Regenerative Medicine Trails, 2017
- Table 4.45 Regenerys, Ltd Details, 2018
- Table 4.46 Regenerys: Regenerative Medicine Clinical Trials, 2017
- Table 4.47 TiGenix NV, Details, 2018
- Table 4.48 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2013-2017
- Table 4.49 Forecast TiGenix: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.50 TiGenix: Regenerative Medicine Clinical Trials, 2017
- Table 4.51 Uniqure Details, 2018
- Table 4.52 Uniqure: Historical Sales ($m) and Operating Profit / Loss ($m), 2015-2017
- Table 3.53 Forecast Uniqure: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.54 UniQure: Regenerative Medicine Clinical Trials, 2018
- Table 4.55 Vericel Corporation, Details, 2018
- Table 4.56 Vericel: Sales by Product ($m) and Revenue Share (%), 2016-2017
- Table 4.57 Vericel: Historical Sales ($m and AGR%), 2013-2017
- Table 3.58 Forecast Vericel: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.59 Vericel Corporation: Regenerative Medicine Clinical Trials, 2017
- Table 4.60 Anika Therapeutics, Inc; Details, 2018
- Table 4.61 Anika Therapeutics, Inc: Financial & Performance Analysis, 2013-2017
- Table 4.62 Anika Therapeutics, Inc: Product Revenue Analysis, ($ Million) 2016-2017
- Table 4.63 Forecast Anika Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.64 Orthofix International, Inc; Details, 2018
- Table 4.65 Orthofix International, Inc: Financial & Performance Analysis, 2012-2017
- Table 4.66 Orthofix International, Inc: Business Units Revenue Analysis, 2014- 2016
- Table 4.67 Orthofix International, Inc: Business Units Revenue Analysis, 2016
- Table 4.68 Forecast Orthofix International, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.69 Orthofix International, Inc: Regenerative Medicine Clinical Trials, 2017
- Table 4.70 Medtronic, Plc; Details, 2017
- Table 4.71 Medtronic, Plc: Financial & Performance Analysis, 2012-2017
- Table 4.72 Medtronic, Plc: Divisional Revenue Analysis, 2014-2017
- Table 4.73 Forecast Medtronic, Plc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.74 Stryker Corporation; Details, 2018
- Table 4.75 Stryker Corporation: Financial & Performance Analysis, 2013-2017
- Table 4.76 Forecast Stryker Corporation: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.77 Acelity, Inc; Details, 2018
- Table 4.78 Acelity, Inc: Financial & Performance Analysis, 2011-2015
- Table 4.79 Forecast Acelity, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.80 Brainstorm Cell Therapeutics, Inc; Details, 2018
- Table 4.81 Brainstorm Cell Therapeutics, Inc: Financial & Performance Analysis, 2015-2017
- Table 4.82 Brainstorm Cell Therapeutics, Inc: Pipeline Development of NurOwn product for different diseases
- Table 4.83 Integra Lifesciences; Details, 2018
- Table 4.84 Integra Lifesciences: Financial & Performance Analysis, 2013-2017
- Table 4.85 Integra Lifesciences: Business Segment Revenue Analysis, 2015-2017
- Table 4.86 Forecast Integra Lifesciences: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.87 Integra Lifesciences: Regenerative Medicine Clinical Trials, 2017
- Table 4.88 Sangamo Therapeutics, Inc; Details, 2018
- Table 4.89 Sangamo Therapeutics, Inc: Financial & Performance Analysis, 2013-2017
- Table 4.90 Forecast Sangamo Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.91 Sangamo Therapeutics: Regenerative Medicine Clinical Trials, 2017
- Table 4.92 Japan Tissue Engineering, Co Ltd; Details, 2018
- Table 4.93 Japan Tissue Engineering, Co Ltd: Financial & Performance Analysis, 2014-2018
- Table 4.94 Forecast Japan Tissue Engineering, Co Ltd: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 4.95 Cytori Therapeutics, Inc; Details, 2018
- Table 4.96 Cytori Therapeutics, Inc: Financial & Performance Analysis, 2012-2017
- Table 4.97 Forecast Cytori Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028
- Table 5.1 Top Five TRM Manufacturers: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
- Table 5.2 TRM Manufacturers by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2012-2017
- Table 5.3 Top 5 TRM Manufacturers ($m): Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
- Table 5.4 Top TRM Manufacturers by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2017-2022
- Table 5.5 Top TRM Manufacturers by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2023-2028
- Table 5.6 Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2018
- List of Figures
- Figure 2.1 European Union Definitions of Regenerative Medicine Products, 2018
- Figure 2.2 Examples of FDA-Approved Tissue Engineering Products
- Figure 2.3 Brief History of Gene Therapy, 1970-2018
- Figure 2.4 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028
- Figure 2.5 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2018
- Figure 3.1 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2017-2028
- Figure 3.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2017-2028
- Figure 3.3 Grafix/Stravix Sales Forecast: Revenue ($m) and AGR (%), 2017-2028
- Figure 3.4 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2017-2028
- Figure 4.1 Alphatec Spine, Inc: Historical Sales ($m) and Operating Loss ($m), 2012-2017
- Figure 4.2 Forecast Alphatec Spine: Revenue ($m), 2017-2028
- Figure 4.3 Anterogen Co Ltd: Historical Sales ($ Thousand) and Operating Loss ($ Thousand), 2014-2017
- Figure 4.4 Forecast Anterogen: Revenue ($m), 2017-2028
- Figure 4.5 Athersys Inc: Historical Sales ($m) 2012-2017
- Figure 4.6 Athersys Inc: Historical Revenue, Expenditure and Losses ($m) 2012-2017
- Figure 4.7 Forecast Athersys Inc: Revenue ($m), 2017-2028
- Figure 4.8 Avita Medical Ltd: Historical Sales ($m, AUD m) and Net Loss ($m), 2013-2017
- Figure 4.9 Forecast Avita Medical Ltd: Revenue ($m), 2017-2028
- Figure 4.10 AxoGen, Inc: Historical Sales ($m) and Net Loss ($m), 2013-2017
- Figure 4.11 Forecast AxoGen, Inc: Revenue ($m), 2017-2028
- Figure 4.12 Medipost Co Ltd: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2013-2017
- Figure 4.13 Medipost: Revenue Share by Business Area (%), 2014
- Figure 4.14 Medipost: Revenue Share by Business Area (%), 2015
- Figure 4.15 Medipost: Revenue Share by Business Area (%), 2016
- Figure 4.16 Medipost: Revenue Share by Business Area (%), 2017
- Figure 4.17 Forecast AxoGen, Inc: Revenue ($m), 2017-2028
- Figure 4.18 Mesoblast: Historical Sales (AUD m), 2013-2017
- Figure 4.19 Forecast Mesoblast: Revenue ($m), 2017-2028
- Figure 4.20 NuVasive, Inc: Historical Sales and Net Income (Profits and Losses) ($m), 2013-2017
- Figure 4.21 Forecast NuVasive, Inc: Revenue ($m), 2017-2028
- Figure 4.22 BioTime Inc: Historical Sales ($m) and Gross Income ($m), 2013-2017
- Figure 4.23 Forecast BioTime Inc: Revenue ($m), 2017-2028
- Figure 4.24 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2013-2017
- Figure 4.25 Forecast Pharmicell: Revenue ($m), 2017-2028
- Figure 4.26 TiGenix: Historical Sales ($m) and Net Income ($m), 2013-2017
- Figure 4.27 Forecast TiGenix: Revenue ($m), 2017-2028
- Figure 4.28 Uniqure: Sales ($m) and Operating Loss (In Thousands), 2015-2017
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook